Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 2009 IP Promotion Plan Calls For Patent Protection for New Dosage and Treatment Regimens
July 13, 2009
- Nissui Pharma. to Market Switch OTC Version of Epadel from Mochida
July 13, 2009
- JSGM Presents Proposals to Promote Use of Generics
July 13, 2009
- Korosho to Inspect Generics Containing 5 More APIs
July 13, 2009
- Lasting Decreases in BP Obtained with Telmisartan + Amlodipine
July 13, 2009
- Concrete Reasons for Lack of Enthusiasm about Use of Generics to Be Determined
July 13, 2009
- R&D NEWS IN BRIEF
July 13, 2009
- Biosimilars Will also Struggle in Japan: Datamonitor
July 13, 2009
- Possible Link between Lantus and Cancer Requires Further Study: EASD
July 13, 2009
- TPA Provides Generics Comparison List Online
July 13, 2009
- Clarify Causes of Gender, Ethnic Differences in Lung Cancer: Dr Kawaguchi
July 13, 2009
- Eiken Licenses LAMP Method to Toshiba
July 13, 2009
- Drug Cost Ratio Remains Virtually Flat at 29.0% in FY2008
July 13, 2009
- Research-Driven Firms Should Not Rely on Off-Patent Products: Mr Kinoshita
July 13, 2009
- TOPICS 2 articles
July 13, 2009
- Korosho to Create Prevention-Oriented Medical Safety System: Mr Mori
July 13, 2009
- Quintiles Leads Int'l Clinical Trials in Asia
July 13, 2009
- REGULATORY NEWS IN BRIEF
July 13, 2009
- Eisai Gives Up Filing Application for Pediatric Indication for Aricept
July 13, 2009
- Astellas to Fill Shortfall in Late-Stage Development with Licensing
July 13, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…